http://www.legislation.gov.uk/id/eur/2009/1024/adopted

http://www.legislation.gov.uk/eur/2009/1024/annexes/adopted

Commission Regulation (EC) No 1024/2009 of 29 October 2009 on the authorisation and refusal of authorisation of certain health claims made on food and referring to the reduction of disease risk and to children’s development and health (Text with EEA relevance)

Commission Regulation (EC) No 1024/2009

2020-12-11

King's Printer of Acts of Parliament

https://webarchive.nationalarchives.gov.uk/eu-exit/https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32009R1024

text

text/xml

Art. 1

The Nutrition (Amendment etc.) (EU Exit) Regulations 2019

reg. 24(2)(a)

reg. 1(1)

Art. 1

The Nutrition (Amendment etc.) (EU Exit) Regulations 2019

reg. 24(2)(b)

reg. 1(1)

Art. 2

The Nutrition (Amendment etc.) (EU Exit) Regulations 2019

reg. 24(3)

reg. 1(1)

Art. 3

The Nutrition (Amendment etc.) (EU Exit) Regulations 2019

reg. 24(4)

reg. 1(1)

Art. 1

The Nutrition (Amendment etc.) (EU Exit) Regulations 2020

reg. 6(3)

reg. 6(4)(c)

reg. 1(2)

Art. 2

The Nutrition (Amendment etc.) (EU Exit) Regulations 2020

reg. 6(3)

reg. 6(4)(c)

reg. 1(2)

ANNEX I

PERMITTED HEALTH CLAIMS

Application — Relevant provisions of Regulation (EC) No 1924/2006	Applicant — Address	Nutrient, substance, food or food category	Claim	Conditions of use of the claim	Conditions and/or restrictions of use of the food and/or additional statement or warning	EFSA opinion reference
Article 14(1)(a) health claim referring to a reduction of a disease risk	Leaf Int and Leaf Holland, Hoevestein 26, 4903 SC Oosterhout NB, The Netherlands, and Leaf Suomi Oy, PO Box 25, FI-21381 Aura, Finland	Chewing gum sweetened with 100 % xylitol	Chewing gum sweetened with 100 % xylitol has been shown to reduce dental plaque. High content/level of dental plaque is a risk factor in the development of caries in children	Information to the consumer that the beneficial effect is obtained with a consumption of 2-3 g of chewing gum sweetened with 100 % xylitol at least 3 times per day after the meals		Q-2008-321
Article 14(1)(b) health claim referring to children’s development and health	Danone SA, C/Buenos Aires, 21, 08029 Barcelona, Spain	Phosphorus	Phosphorus is needed for the normal growth and development of bone in children	The claim can be used only for food which is at least a source of phosphorus as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006		Q-2008-217

ANNEX II

REJECTED HEALTH CLAIMS

Application — Relevant provisions of Regulation (EC) No 1924/2006	Nutrient, substance, food or food category	Claim	EFSA opinion reference
Article 14(1)(b) health claim referring to children’s development and health	Lactoral	Lactoral helps to bring back the normal functioning of the alimentary tract during its microflora disturbances (for example in case of loose stools, after taking antibiotics, in case of intestinal disorders caused by enteric pathogens)	EFSA-Q-2008-269
Article 14(1)(b) health claim referring to children’s development and health	Lactoral	Lactoral is recommended in order to improve the general immunity by maintaining the microbiological balance	EFSA-Q-2008-477
Article 14(1)(b) health claim referring to children’s development and health	Lactoral	Lactoral helps to protect the alimentary system against enteric pathogens because of strong antagonistic properties and helps to build the natural intestinal barrier	EFSA-Q-2008-478
Article 14(1)(b) health claim referring to children’s development and health	Lactoral	Lactoral helps to maintain natural intestinal microflora during travel, changing the climatic zone or a diet, especially in poor hygiene conditions	EFSA-Q-2008-479
Article 14(1)(b) health claim referring to children’s development and health	Lactoral	Lactoral contains living probiotic bacteria with strong ability to intestinal tract colonisation, isolated from healthy, naturally fed infant	EFSA-Q-2008-480
Article 14(1)(b) health claim referring to children’s development and health	Mumomega®	Mumomega® provides the nourishments that support healthy central nervous system development	EFSA-Q-2008-328
Article 14(1)(b) health claim referring to children’s development and health	Efalex®	Efalex® may help maintain coordination	EFSA-Q-2008-121
Article 14(1)(b) health claim referring to children’s development and health	Efalex®	Efalex® may help maintain concentration	EFSA-Q-2008-317
Article 14(1)(b) health claim referring to children’s development and health	Efalex®	Efalex® may help maintain and support brain development and function	EFSA-Q-2008-318
Article 14(1)(b) health claim referring to children’s development and health	Efalex®	Efalex® may help maintain learning ability	EFSA-Q-2008-319
Article 14(1)(b) health claim referring to children’s development and health	Efalex®	Efalex® may help maintain and support eye development and function	EFSA-Q-2008-320
Article 14(1)(b) health claim referring to children’s development and health	Eye q baby®	Eye q baby® provides the nourishments that support healthy central nervous system development	EFSA-Q-2008-119
Article 14(1)(b) health claim referring to children’s development and health	Eye q®	Eye q® provides the nourishments that help children to maintain healthy brain functions	EFSA-Q-2008-329
Article 14(1)(b) health claim referring to children’s development and health	Eye q®	Eye q® provides the nourishments that help children to maintain concentration levels	EFSA-Q-2008-330